Clinical Trials on Meningococcal Infections

Total 56296 results

Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Public Health England

Completed

Comparison of Two Meningococcal ACWY Conjugate Vaccines (PRIME)

Meningococcal Meningitis

United Kingdom
JN-International Medical Corporation

Completed

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Meningococcal Infections | Meningococcal Meningitis

Argentina, Chile, Czech Republic, Hungary, Italy
Armauer Hansen Research Institute, Ethiopia
World Health Organization; Addis Ababa University; LSHTM,UK

Completed

Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine (ETH-TVT)

Meningococcal Meningitis

Ethiopia
Novartis Vaccines

Completed

Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

Meningococcal Disease

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Meningococcal Disease

Italy, Poland, Russian Federation, Spain, United Kingdom
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Meningococcal Disease

Korea, Republic of
Novartis Vaccines

Completed

Safety Surveillance of MenACWY-CRM Vaccine in Children

Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Novartis Vaccines

Completed

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Meningococcal Meningitis

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers

Meningococcal Meningitis

Germany
Sanofi

Completed

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Center for Vaccine Development - Mali
University College, London; University of Oxford; Public Health England; University... and other collaborators

Recruiting

A Human Controlled Infection Study With Neisseria Lactamica in Malian Adults

Meningitis, Meningococcal

Mali
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (MEQ00064)

Healthy Volunteers | Meningococcal Immunisation

South Africa, India
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Healthy Volunteers | Meningococcal Immunisation

Spain, Hungary, Italy, Singapore
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Spain, Finland, Germany, Hungary
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
GlaxoSmithKline

Active, not recruiting

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Infections, Meningococcal

United States, Italy
GlaxoSmithKline

Active, not recruiting

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Infections, Meningococcal

United States, Puerto Rico
GlaxoSmithKline

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

Infections, Meningococcal

Germany, Canada, Australia, Belgium, Italy
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Infections, Meningococcal

United States
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

Meningococcal Sero-type C Infection

Canada
The Immunobiological Technology Institute (Bio-Manguinhos)...

Unknown

Conjugate Vaccine Against Meningococcus C a Brazilian Project

Serogroup C Meningococcal Meningitis

Brazil
Novartis Vaccines

Completed

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Meningococcal Disease

United States, Ukraine
University Hospital, Rouen

Completed

Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection

Meningococcal Infections

France
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Not yet recruiting

A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

Meningococcal Meningitis

China
CanSino Biologics Inc.

Not yet recruiting

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Meningococcal Meningitis
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Meningitis, Meningococcal, Serogroup B

United States
Novartis

Completed

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Meningitis, Meningococcal, Serogroup B

Poland
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos

Meningitis, Meningococcal, Serogroup C

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Serum Institute of India Pvt. Ltd.
PATH

Completed

Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)

Meningococcal Meningitis

Gambia, Mali
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guizhou Center for Disease Control... and other collaborators

Unknown

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Meningitis | Meningococcal Infections | Meningococcal Meningitis

China
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Meningococcal Meningitis

Finland, Poland
Lanzhou Institute of Biological Products Co., Ltd
Air Force Military Medical University, China

Unknown

A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine

Meningococcal Meningitis

China
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

Meningococcal Infections | Meningococcal Meningitis

Argentina, Colombia
Sanofi Pasteur, a Sanofi Company

Completed

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Meningococcal Infections | Meningococcal Meningitis

United States
JN-International Medical Corporation

Completed

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

Meningococcal Infections | Meningococcal Meningitis

United States
St George's, University of London
Public Health England

Recruiting

Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study

HIV/AIDS | Meningococcal Disease

United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants

Infections, Meningococcal

3

Subscribe